Long-term Effects of Vasodilators in Combined Pulmonary Fibrosis and Emphysema with Severe Pulmonary Hypertension: A Case Report

(E-pub Ahead of Print)

Author(s): Fuschillo Salvatore, Alberto De Felice, Roberta Maria Rosaria Di Grazia, Mauro Maniscalco*.

Journal Name: Current Respiratory Medicine Reviews

Volume 14 , 2018


Background: Combined pulmonary fibrosis and emphysema (CPFE) is defined by imaging findings and is characterized by the coexistence of both upper lobe emphysema and lower lobe pulmonary fibrosis. The natural course of CPFE is frequently complicated by pulmonary arterial hypertension (PAH), which identifies the most severe CPFE phenotype with a particularly poor prognosis.

Case Report: In June 2013, a 78-year-old white male was admitted to the pulmonary rehabilitation program because of exertional dyspnea. In 2007, he was diagnosed as CPFE due to imaging findings. After diagnosis, the patient remained stable until 2011, when he started to get short of breath with exertion. From September 2011, disease progression and worsening of the patient’s clinical condition increased at a faster rate. During the hospitalization, a trans-thoracic two-dimensional echocardiography showed the left ventricular chamber slightly dilated with an ejection fraction of 40% and systolic/diastolic/mean pulmonary arterial pressures on the right heart catheterization were 71/24/44 mmHg. Upon progressive clinical worsening, not due to worsening of lung function tests but to the increase in PAH, an off-label use of ambrisentan was initiated as monotherapy and, then, tadalafil was added. This therapy obtained an improvement in both clinical condition and exercise capacity. Despite the advanced stage of lung disease, the patient survived for about 2 years after the start of treatment with ambrisentan and tadalafil.

Conclusion: Some of the patients affected by CPFE complicated by PAH could benefit from the addition of pulmonary vasodilator agents to conventional treatment.

Keywords: Combined pulmonary fibrosis and emphysema; Pulmonary arterial hypertension; Vasodilators; Ambrisentan; Tadalafil

Rights & PermissionsPrintExport

Article Details

Year: 2018
(E-pub Ahead of Print)
DOI: 10.2174/1573398X14666180212115511
Price: $95

Article Metrics

PDF: 0
PRC: 0